Waltham, Mass., September 3, 2026

Dyne Therapeutics announced that it will present new preclinical data supporting the development of four investigational therapies for Duchenne muscular dystrophy (DMD) at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting. The programs include DYNE-253, DYNE-245, DYNE-244 and DYNE-255, which are being developed for DMD patients amenable to exon skipping of exons 53, 45, 44 and 55, respectively. All four candidates are advancing into IND-enabling studies, expanding Dyne’s potential DMD franchise beyond its exon 51 program.

FORCE Platform Supports Broad DMD Exon-Skipping Strategy

The four development candidates leverage Dyne’s FORCE™ platform, the same technology being used by zeleciment rostudirsen (z-rostudirsen, DYNE-251), which is currently under FDA review for DMD amenable to exon 51 skipping. Dyne said the new preclinical findings strengthen confidence in the platform’s ability to deliver exon-skipping oligonucleotides to tissues relevant to DMD and generate meaningful exon skipping and dystrophin production. The strategy is designed to address additional DMD mutations and potentially broaden access to targeted genetic therapies.

Dyne Reports Exon-Skipping and Dystrophin Data

The data to be presented will include in vitro exon-skipping results for DYNE-253, DYNE-245, DYNE-244 and DYNE-255, providing preclinical evidence supporting continued development of the four candidates. Dyne will also present in vivo pharmacokinetic and pharmacodynamic results for DYNE-253, including measurements of exon skipping and dystrophin levels in a Del52 mouse model of DMD. These findings are intended to evaluate the ability of the FORCE platform to deliver therapeutic payloads and drive molecular effects relevant to the underlying disease.

Advertisement

cGxPJobs Banner

Dyne Therapeutics Targets Multiple DMD Mutations with IND-Enabling Programs

Dyne plans to present the findings under the poster title “Delivering for DMD: Leveraging the FORCE platform to deliver exon skipping oligonucleotides for a broad set of DMD patients.” The presentation is scheduled for September 25, 2026, during the NMSG Scientific Meeting in San Antonio, Texas. As z-rostudirsen advances through FDA review for exon 51 DMD, Dyne is simultaneously progressing its additional exon-skipping candidates toward IND-enabling studies, with the broader strategy focused on developing therapies for multiple genetically defined DMD populations.

Source:Dyne Therapeutics,press relese